Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-22
    E.g., 2018-09-22


51716 items
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

New Pharmadigm CEO

Ned Weinshenker was appointed president and CEO of Pharmadigm (Salt Lake City, Utah). Weinshenker, formerly president of Churchill Oaks Consulting, succeeds Martin McGlynn, effective Oct. 1....
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

TCPI president and chairman retires

TCPI, a point-of-care diagnostics company, announced the retirement of Jack Aronowitz, who will remain as a director and consultant. Elliott Block will become president, while remaining CEO, and Martin Gurkin, retired TCPI COO and senior...
12:00 AM, Sep 14, 2000  |  BC Extra | Top Story

Xoma reports Phase III Neuprex data

XOMA published in The Lancet results of its Phase III study of Neuprex opebecan recombinant bactericidal/permeability-increasing protein (rBPI-21) in 393 pediatric patients with severe meningococcemia, showing that Neuprex did not significantly affect mortality rate...
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

eBioinformatics deal with Qiagen subsidiary

eBioinformatics (Pleasanton, Calif.) will combine its online DNA primer design application with the custom DNA synthesis and delivery service of Operon Technologies, a subsidiary Qiagen (NMarkt:QIA; QGENF)....
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

Ceptyr and Lilly form drug discovery collaboration

The companies formed a two-year collaboration to discover small molecules to treat diabetes, obesity and impaired glucose tolerance. The collaboration will focus on the phosphatase target PTP1B, using Ceptyr's assays and screening technology. Ceptyr (Bothell,...
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

SmithKline to develop Novavax HEV technology

NOX said the National Institute for Allergy and Infectious Diseases, its partner in developing recombinant hepatitis E virus clones and antigen production technology, has licensed the technology to SBH for the development of a vaccine....
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

Applied Molecular Evolution grants Idexx sub-license

IDXX received a non-exclusive sub-license for AMEV's Kauffman patents for directed evolution. The patents cover methods of stochastically generating proteins, which AMEV believes is required by many directed evolution technologies. IDXX will use the patents...
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

Schwarz in CNS deal

Schwarz Pharma (Monheim, Germany) and the neurology center of the Universitatsklinikum Freiburg (Freiburg, Germany) will jointly develop compounds for neurodegenerative diseases. Schwarz will have worldwide rights to the compounds, which are in preclinical development....
12:00 AM, Sep 14, 2000  |  BC Extra | Company News

Agritope plant transformation deal with Rohm and Haas

The companies will combine AGTO's visual marker gene technology with ROH's ligand-inducible gene expression technology to develop a plant transformation marker selection system. ROH will contribute its synthetic ecdysone receptors and ligand inducer chemistry for...
12:00 AM, Sep 14, 2000  |  BC Extra | Clinical News

Emisphere enrollment less than expected

EMIS said that it will not complete by year end its double-blind Phase III trial comparing its oral heparin with Lovenox from Aventis (AVE) to treat deep vein thrombosis. The company had initially targeted 95...